Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer.
Charles G DrakeRussell K PachynskiSumit K SubudhiDouglas G McNeelEmmanuel S AntonarakisTodd M BauerPeter LauerDirk BrockstedtDaniel PatriciaMark WadeEnrique ZudaireNibedita BandyopadhyayDolly A ParasrampuriaSuzette GirgisGary E MasonRoland E KnoblauchNicole StoneJeffrey R InfanteMarco M GottardisLawrence FongPublished in: Prostate cancer and prostatic diseases (2021)
JNJ-809 has manageable safety consistent with other LADD Lm-based therapies. Limited antigen-specific immune responses were observed, which did not translate into objective clinical responses.